Moderna announced that Chief Medical Officer Jacqueline Miller will step down effective March 2, 2026, and that former oncology executive David Berman will assume the role of Chief Development Officer on the same date.
Miller, who was promoted to CMO in November 2024 after more than four years as Senior Vice President and Therapeutic Area Head for Infectious Diseases, led the development of the company’s Spikevax COVID‑19 vaccine. She will remain with Moderna as a consultant to support a smooth transition.
Berman brings a decade of experience in oncology and rare‑disease therapeutics, having led several successful product launches at his previous employer. His appointment signals Moderna’s intent to deepen its focus on mRNA‑based oncology and rare‑disease programs, areas that have become central to the company’s long‑term strategy as demand for COVID‑19 vaccines wanes.
The leadership change occurs amid Moderna’s broader pivot from a vaccine‑centric model to a diversified mRNA platform. Recent strategic moves, such as the Recordati collaboration to commercialize mRNA‑3927, have derisked the company’s rare‑disease pipeline and attracted investor attention. At the same time, the company faces headwinds from declining COVID‑19 vaccine demand and anti‑vaccine sentiment, which have prompted a reassessment of late‑stage vaccine investments.
Berman’s oncology expertise is expected to strengthen Moderna’s pipeline in personalized cancer vaccines and other mRNA therapeutics, while Miller’s continued consulting role should preserve institutional knowledge and minimize disruption to ongoing vaccine and therapeutic development programs. The transition is therefore viewed as a strategic alignment rather than a destabilizing event.
Market analysts noted a mixed reaction: the Recordati partnership and Berman’s appointment were seen as positive catalysts for the company’s non‑vaccine business, whereas Miller’s departure raised short‑term governance concerns. Overall sentiment remained cautious, reflecting the company’s ongoing shift away from its pandemic‑era revenue streams.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.